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MEDICAL MARIJUANA POST-MCINTOSH 
 
Robert L. Greenberg1 
 
INTRODUCTION 
On August 16, 2016, the United States Court of Appeals for the Ninth 
Circuit issued a landmark decision on a series of cases relating to businesses 
and individuals in the state-legal cannabis business. In United States v. 
McIntosh,2 the Court heard ten cases challenging the United States 
Department of Justice (DOJ) prosecution of medical marijuana patients.  
These cases involved criminal defendants who were charged with violations 
of federal narcotics laws while ostensibly in compliance with the laws of 
their respective states.3 The court determined that federal law prohibits the 
prosecution of these cases when the defendants are otherwise in compliance 
with state law.  The impact of this decision is discussed infra. 
 
I. THE UNDERLYING LAW 
 
McIntosh deals with a unique interplay of conflicting statutes: the 
Controlled Substances Act and the Continuing Appropriations Acts of 2015 
and 2016. The former proscribes the possession, sale, and use of marijuana 
in any form, and the latter prohibit the DOJ from interfering with state 
medical marijuana laws. 
 
                                                
1 Robert L. Greenberg, Esq., is the Principal at Robert L. Greenberg, P.C. and is an 
Adjunct Instructor of Law at Bramson ORT College. 
2 United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016).  
3 The matter was “remand[ed] with instructions to conduct an evidentiary hearing to 
determine whether Appellants have complied with state law.”  Id. at 1179.  No legal 
determination was made regarding whether the defendants were in compliance with state 
law. See generally id.  
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A.  The Controlled Substances Act 
 
Marijuana—medical or otherwise—remains a Schedule 1 drug under 
the Controlled Substances Act.4 Being listed as a Schedule 1 drug means 
that there is no legitimate medical usage for marijuana.5The decision in 
McIntosh does not affect the Controlled Substances Act. Further discussion 
of this decision’s impact is found infra. However, several states have 
enacted medical marijuana laws that license organizations to grow and 
distribute cannabis products for limited medical purposes and license 
patients to purchase and consume them. The state and federal laws come 
into conflict in these states. 
Previously, in Gonzales v. Raich, the United States Supreme Court 
found that the states may not permit what federal law prohibits.6 What is 
left is a statutory and regulatory scheme in which individuals and 
organizations are in compliance with state law, but in violation of federal 
law.   
B.  The Continuing Appropriations Acts  
 
In 2014 and again in 2015, Congress passed Continuing Appropriations 
Acts that contained a clause withholding funds from the DOJ in order to 
prevent the DOJ from interfering with state medical marijuana laws. The 
Court’s decision points to these Continuing Appropriations Acts of 2015 
and 2016.7 The latter of these acts states:  
None of the funds made available in this Act to the Department of Justice 
may be used, with respect to any of the States of Alabama, Alaska, 
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, 
Hawaii, Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, 
Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee, 
Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming, 
or with respect to the District of Columbia, Guam, or Puerto Rico, to 
prevent any of them from implementing their own laws that authorize the 
use, distribution, possession, or cultivation of medical marijuana.8 
                                                
4 21 U.S.C. § 812(c)(10) (2012).  
5 Id. § 812(b)(1) (explaining that Schedule 1 drugs must have a “high potential for 
abuse” and “a lack of accepted safety for use of the drug or other substance under medical 
supervision”). 
6 Gonzales v. Raich, 545 U.S. 1, 29 (2005) (“The Supremacy Clause unambiguously 
provides that if there is any conflict between federal and state law, federal law shall 
prevail.”). 
7 McIntosh, 833 F.3d at 1169-70. 
8 Consolidated Appropriations Act, 2016, Pub. L. No. 114-113, § 542, 129 Stat. 2242, 
2332-33 (2015).  
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These states and territories (together the “Medical Marijuana States”)9 have 
already passed laws that authorize patients to receive medical marijuana as 
a treatment for various ailments.In its operation, the Department of Justice 
may not use the funds allocated to it to enforce the general prohibitions on 
marijuana as a Schedule I Narcotic against those individuals in compliance 
with state law.10 
 
II. CONGRESS’S “POWER OF THE PURSE” IN THE CONSTITUTION 
 
A. Defining Congress’s Check on the Executive Branch 
 
Article I of the United States Constitution grants Congress the “power 
of the purse.”11 The Constitution states, “No Money shall be drawn from the 
Treasury, but in Consequence of Appropriations made by Law[.]”12 This 
power means that no actions may be taken by the Executive without the 
explicit approval of Congress. This clause is a basic example of checks-and-
balances: without Congress approving the funds, the Executive Branch 
cannot do anything.13 
 
B. Applying This Principle to the Department of Justice 
 
The question before the Court was whether the Department of Justice 
was drawing funds in violation of the Continuing Appropriations Acts.14  
The language of the Acts was written only to prohibit the DOJ from 
preventing “any of [the Medical Marijuana States] . . . from implementing 
                                                
9 McIntosh, 833 F.3d at 1175, 1175 n.3. Since the elections on November 8, 2016, an 
additional two states – Arkansas and North Dakota – will allow medical marijuana usage, 
while three new states voted to legalize recreational marijuana use as well. See Christopher 
Ingraham, Marijuana Wins Big on Election Night, WASH. POST (Nov. 8, 2016), 
https://www.washingtonpost.com/news/wonk/wp/2016/11/08/medical-marijuana-sails-to-
victory-in-florida [https://perma.cc/49F6-4M6H].  
10 David Stout & Solomon Moore, U.S. Won’t Prosecute in States That Allow Medical 
Marijuana, N.Y. TIMES (Oct. 19, 2009), 
http://www.nytimes.com/2009/10/20/us/20cannabis.html [https://perma.cc/EK77-A8KN].  
11 See, e.g., Power of the Purse, U.S. HOUSE OF REPRESENTATIVES HISTORY, ART & 
ARCHIVES, http://history.house.gov/institution/origins-development/power-of-the-purse 
[https://perma.cc/N2X3-EUPG] (last visited Aug. 30, 2016). 
12 U.S. CONST. art. I, § 9, cl. 7. 
13 See Office of Pers. Mgmt. v. Richmond, 496 U.S. 414, 424 (1990).  
14 McIntosh, 833 F.3d at 1168 (“We are asked to decide whether criminal defendants 
may avoid prosecution for various federal marijuana offenses on the basis of a 
congressional appropriations rider that prohibits the United States Department of Justice 
from spending funds to prevent states’ implementation of their own medical marijuana 
laws.”). 
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their own laws that authorize the use, distribution, possession, or cultivation 
of medical marijuana.”15 The question then became: Does this prohibit the 
DOJ from prosecuting individuals in these states who are in compliance 
with their state laws?  
The Court summarized the federal government’s arguments and 
responded as follows: 
DOJ argues that it does not prevent the Medical Marijuana States from 
giving practical effect to their medical marijuana laws by prosecuting 
private individuals, rather than taking legal action against the state. We are 
not persuaded. 
. . .  
DOJ, without taking any legal action against the Medical Marijuana 
States, prevents them from implementing their laws that authorize the use, 
distribution, possession, or cultivation of medical marijuana by 
prosecuting individuals for use, distribution, possession, or cultivation of 
medical marijuana that is authorized by such laws. By officially permitting 
certain conduct, state law provides for non-prosecution of individuals who 
engage in such conduct. If the federal government prosecutes such 
individuals, it has prevented the state from giving practical effect to its law 
providing for non-prosecution of individuals who engage in the permitted 
conduct. 
We therefore conclude that, at a minimum, [the Continuing Appropriation 
Act] prohibits DOJ from spending funds from relevant appropriations acts 
for the prosecution of individuals who engaged in conduct permitted by 
the State Medical Marijuana Laws and who fully complied with such laws. 
16 
The Court concluded that Congress forbade the DOJ from enforcing the 
laws against individuals who are in compliance with state law. The DOJ 
may not go after individuals who are in compliance.  
 
III. WHAT THIS DECISION MEANS 
 
This decision is far reaching in its holding that enforcement of the 
Controlled Substances Act is estopped in the Medical Marijuana States 
when those who would be prosecuted are in compliance with their state 
laws.  Medical Marijuana businesses and individuals are safe from 
prosecution as long as they maintain compliance with state medical 
marijuana laws. 
 
 
                                                
15 Consolidated Appropriations Act, 2016, Pub. L. No. 114-113, § 542, 129 Stat. 2242, 
2332-33 (2015). 
16 McIntosh, 833 F.3d at 1176-77 (emphasis added). 
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A. Legality of Cannabis in These States 
 
Federal law, namely the Controlled Substances Act, remains the law of 
the land. As the McIntosh court explained, this decision does not change the 
underlying prohibition of marijuana under federal law: 
To be clear, [the Consolidated Appropriations Act] does not provide 
immunity from prosecution for federal marijuana offenses. The 
[Controlled Substances Act] prohibits the manufacture, distribution, and 
possession of marijuana. Anyone in any state who possesses, distributes, 
or manufactures marijuana for medical or recreational purposes (or 
attempts or conspires to do so) is committing a federal crime. The federal 
government can prosecute such offenses for up to five years after they 
occur. Congress currently restricts the government from spending certain 
funds to prosecute certain individuals. But Congress could restore funding 
tomorrow[.]  .  .  .  
Nor does any state law ‘legalize’ possession, distribution, or manufacture 
of marijuana. Under the Supremacy Clause of the Constitution, state laws 
cannot permit what federal law prohibits. Thus, while the CSA remains in 
effect, states cannot actually authorize the manufacture, distribution, or 
possession of marijuana. Such activity remains prohibited by federal 
law.17 
The current act only prohibits the DOJ from using federal funding to go 
after those in the Medical Marijuana States who are in compliance with 
their state law. It does not change the underlying fact that these individuals 
are not in compliance with federal law. Appropriation acts are temporary 
measures and—as the court notes—the law could change tomorrow. It does 
not discuss recreational marijuana, which is presumably still illegal after 
this decision; the court only addresses how medical marijuana will not be 
prosecuted. Medical Marijuana remains illegal under federal law, and will 
remain so. The DOJ is enjoined from enforcing the Controlled Substances 
Act with respect to marijuana, but this decision does not change the 
underlying law. 
 
B. Federal Enforcement of the Law in Medical Marijuana States 
 
This decision does not prohibit DOJ from enforcing federal law in these 
Medical Marijuana States, and this decision does not protect individuals 
who are not in compliance with state law. As the court explained, 
“[i]ndividuals who do not strictly comply with all state-law conditions  .  .  .  
have engaged in conduct that is unauthorized, and prosecuting such 
individuals” is legal.18 It is also important to note that this decision is very 
                                                
17 Id. at 1179 n.5 (emphasis added) (internal citations omitted). 
18 Id. at 1178.   
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recent and the only one thus far that explicitly prohibits the federal 
government from prosecuting legal medical marijuana users and businesses. 
This decision does not affect the DOJ’s ability to prosecute recreational 
marijuana users and businesses, even if they are in compliance with state 
law. Even though the particular business may still be in compliance with 
state law, since it is recreational and not medical, it is still violating the 
federal Controlled Substances Act.19   
 
C. Impact of the Decision in Newer-Legalizing States 
  
This recent decision has a far-reaching impact throughout the country. 
The Ninth Circuit covers the western part of the United States,20 which has 
largely lead the way in the legalization of medical marijuana (and also the 
legalization of recreational marijuana). Subject to further appellate review 
and a petition for certiorari, McIntosh is good law. This, in conjunction 
with the Cole memorandum,21 should provide some safe harbor to those 
individuals and businesses that are in the legal medical marijuana business 
in the rest of the United States.   
Maintaining compliance with state law is not an easy task, however. For 
example, the New York Compassionate Care Act,22 which authorizes 
medical marijuana, is still relatively new, with only five approved providers 
in the state.23 Its rules are strict—including the prohibition of any 
smokeable forms of marijuana.24 Patients cannot grow their own plants and 
                                                
19 Id. at 1179 n.5. 
20 U.S. COURTS, GEOGRAPHIC BOUNDARIES OF UNITED STATES COURTS OF APPEALS 
AND UNITED STATES DISTRICT COURTS (2016), http://www.uscourts.gov/file/document/us-
federal-courts-circuit-map [https://perma.cc/XG8X-M7X2]. 
21 Memorandum from James M. Cole, Deputy Att’y Gen., U.S. Dep’t of Justice, on 
Guidance Regarding Marijuana Enforcement (Aug. 29, 2013), 
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf 
[https://perma.cc/NEU4-5BRH]. 
22 Assemb. 6357-E, 2013 Leg., 237th Sess. (N.Y. 2014), 
http://assembly.state.ny.us/leg/?term=2013&bn=A06357; see also New York State Medical 
Marijuana Program, N.Y. STATE DEP’T OF HEALTH, 
http://www.health.ny.gov/regulations/medical_marijuana [https://perma.cc/ZY55-TELU] 
(last visited Aug. 24, 2016). 
23 N.Y. STATE DEP’T OF HEALTH, MEDICAL USE OF MARIJUANA UNDER THE 
COMPASSIONATE CARE ACT: TWO-YEAR REPORT 2-3 (2016) [hereinafter TWO-YEAR 
REPORT], 
http://www.health.ny.gov/regulations/medical_marijuana/docs/two_year_report.pdf 
[https://perma.cc/UNE6-ZU73]; see also New York State Medical Marijuana Program: 
Registered Organizations, N.Y. STATE DEP’T OF HEALTH, 
http://www.health.ny.gov/regulations/medical_marijuana/application/selected_applicants.ht
m [https://perma.cc/GVK8-EFDL] (last visited Aug. 24, 2016). 
24 TWO-YEAR REPORT, supra note 22, at 4 (“Smoking and edible products are not 
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can only get their medical marijuana in limited doses and at registered 
facilities.25 There have not been any determinations of compliance under 
New York’s law yet. 
Ultimately, this provides some comfort to those who are adhering to the 
law and regulations promulgated by the states. As the state regulatory 
schemes mature, it will become clear for those in the industry and their 
patients how to maintain compliance and avoid federal prosecution. 
 
* * * 
 
                                                                                                                       
permitted.”). 
25 New York State Marijuana Program: Frequently Asked Questions, N.Y. STATE 
DEP’T OF HEALTH, http://www.health.ny.gov/regulations/medical_marijuana/faq.htm 
[https://perma.cc/DPV9-T8H5] (last visited Oct. 19, 2016). 
